IMMUNOME INC (IMNM) Stock Price, Quote, News and Overview
NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD
IMNM Quote, Performance and Key Statistics
IMMUNOME INC
NASDAQ:IMNM (1/30/2025, 5:20:01 PM)
After market: 10.36 -0.15 (-1.43%)10.51
+1.16 (+12.41%)
The current stock price of IMNM is 10.51 USD. In the past month the price increased by 2.24%. In the past year, price decreased by -35.48%.
IMNM Latest News, Press Releases and Analysis
Curious about the stocks that are showing activity after the closing bell on Wednesday?
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Immunome Announces Pricing of Upsized Public Offering of Common Stock
Immunome Announces Proposed Public Offering of Common Stock
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
IMNM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.34 | 310.40B | ||
| AMGN | AMGEN INC | 14.78 | 152.67B | ||
| GILD | GILEAD SCIENCES INC | 21.88 | 120.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 859.61 | 112.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.04 | 75.06B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.75B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.13B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.16B | ||
| NTRA | NATERA INC | N/A | 23.27B | ||
| BIIB | BIOGEN INC | 8.95 | 21.31B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.49B |
Related stock screener links
About IMNM
Company Profile
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 55 full-time employees. The company went IPO on 2020-10-02. The firm's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. The company also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Company Info
IMMUNOME INC
18702 N. Creek Parkway, Suite 100
Bothell WASHINGTON 19341 US
CEO: Purnanand D. Sarma
Employees: 78
Company Website: https://immunome.com/
Investor Relations: http://investors.immunome.com
Phone: 16103213700
IMNM FAQ
What is the stock price of IMNM?
The current stock price of IMNM is 10.51 USD.
What is the symbol for IMMUNOME INC stock?
The exchange symbol of IMMUNOME INC is IMNM and it is listed on the Nasdaq exchange.
On which exchange is IMNM stock listed?
IMNM stock is listed on the Nasdaq exchange.
Is IMNM a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IMNM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IMNM.
Does IMNM stock pay dividends?
IMNM does not pay a dividend.
What is the Price/Earnings (PE) ratio of IMNM?
IMNM does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.89).
What is the Short Interest ratio of IMNM stock?
The outstanding short interest for IMNM is 19.06% of its float.
IMNM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IMNM. When comparing the yearly performance of all stocks, IMNM is a bad performer in the overall market: 88.45% of all stocks are doing better.
IMNM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMNM. No worries on liquidiy or solvency for IMNM as it has an excellent financial health rating, but there are worries on the profitability.
IMNM Financial Highlights
Over the last trailing twelve months IMNM reported a non-GAAP Earnings per Share(EPS) of -7.89. The EPS increased by -234.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -118.86% | ||
| ROE | -142.08% | ||
| Debt/Equity | 0 |
IMNM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to IMNM. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -350.78% and a revenue growth -23.24% for IMNM